. Update on florbetapir F 18 (18F-AV-45) PET clinical studies. Human Amyloid Imaging 2010 Meeting Abstracts. 2010 April 9;


Abstract: Avid Radiopharmaceuticals is currently conducting a phase III clinical study of subjects at the end of life with and without neurodegenerative dementia. A planned interim analysis of the first six subjects brought to autopsy has been performed comparing histopathology to quantitative and qualitative assessments of amyloid PET imaging.

Subjects who were ≥18 years old and willing to consent to a brain autopsy were admitted to the study if they had a life expectancy of Of the six subjects, 4 had a clinical diagnosis at the time of imaging of AD, one had a clinical diagnosis of Parkinson’s disease with dementia (PDD), and one had no clinical evidence of dementia. The mean age was 76 (range 47-86). Histopathology, CERAD neuritic plaque scores, florbetapir PET SUVr values, and visual ratings of grey matter retention will be presented and compared for the six autopsy cases.


Please login to recommend the paper.


No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:


  1. Toronto: HAI Amyloid Imaging Conference Abstracts